Enliven Therapeutics, Inc.

ELVN · NasdaqGS · Stock · Healthcare

$39.28

-0.53% today

Delayed price, 2026-10-14 20:18 UTC

What Enliven Therapeutics does

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Key facts

Sector

Healthcare

Industry

Biotechnology

Market cap

$2.88B

P/E (ttm)

—

Forward P/E

-16.7

Dividend yield

0.00%

Beta

0.34

Profit margin

0.0%

Employees

Headquarters

Boulder, CO, United States

Exchange

NasdaqGS

Website

www.enliventherapeutics.com

Performance

1 Month

-20.6%

3 Months

-26.2%

6 Months

-18.4%

1 Year

+83.5%

5 Years

+190.5%

$14.7952-week range$62.32

Biggest setback — last 12 months

-35.0%

3 Aug 2026 → 14 Oct 2026

Fell from $60.46 to $39.28 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+289.1%

29 Dec 2025 → 3 Aug 2026

Ran from $15.54 to $60.46 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Below long-term trend

Price sits below its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$33.06 (-15.8%)	$39.28	$46.67 (+18.8%)
3 Months	$29.14 (-25.8%)	$39.28	$52.95 (+34.8%)
6 Months	$25.75 (-34.4%)	$39.28	$59.91 (+52.5%)
12 Months	$21.62 (-45.0%)	$39.28	$71.36 (+81.7%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 59.7%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Tarsus Pharmaceuticals, Inc.

$72.29 · +2.1%

AMLX

Amylyx Pharmaceuticals, Inc.

$27.03 · +0.7%

CURA.TO

Curaleaf Holdings, Inc.

Amneal Pharmaceuticals, Inc.

$18.90 · -3.4%

Recent headlines

Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML Strategy — Simply Wall St.Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia — PR Newswire

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.